Alzamend Neuro, Inc. (ALZN)

NASDAQ: ALZN · USD

$1.46

+0.21 (+16.8%)· Recorded snapshot

Market cap	7M
Net income (ttm)	-9.1M
EPS (ttm)	-$2.31
Shares out	4.8M
Volume	241,247.625
Beta	0.27

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -9.1M
EPS (ttm): -$2.31
Market cap: 7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 14:30 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-163.2

P25 n/aP50 n/aP75 n/a

ROIC-102

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ALZN indicators

Market & fundamental data

Available fields

183

Groups with data

Currency

USD

Showing 183 of 183 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001677077
Company name	Alzamend Neuro, Inc.
Country	United States
Country code	US
CUSIP number	02262M605
Earnings date	2026-12-08
Earnings time	amc
Employees	6
Employees change	0
Employees growth	0%
Enterprise value	$-545,888
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-07-31
First seen	2026-05-09
Fiscal year end	April
Founded	2016
Industry	Biotechnology
IPO date	2021-06-15
Is primary listing	Yes
Is SPAC	No
ISIN number	US02262M6057
Last 10-K release date	2026-07-22
Last earnings date	2026-09-10
Last refreshed	2026-11-04
Last stock split date	2025-05-12
Last stock split type	Reverse
Market cap	$7M
Market cap category	Nano-Cap
Next earnings date	2026-12-08
Options	No
Price	$1.46
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-11-03
Symbol	ALZN
U.S. state	Georgia
Website	https://www.alzamend.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-158.53%
FCF / EV yield	1,253.65%
FCF yield	-97.13%
P/B ratio	1.21x
Price / tangible book value	1.21x
Sector forward P/E	23.32x
Sector P/E	49.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.5M
ROA	-76.44%
ROA (5Y)	-128.09%
ROCE	-156.69%
ROE	-163.23%
ROE (5Y)	-1,156.21%
ROIC	-101.96%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	12
EPS growth years	3
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$110,740
EBIT	$-9.1M
EBITDA	$-9M
EPS	$-2.31
FCF per share	$-1.42
Financing cash flow	$8.8M
Free cash flow	$-6.8M
Free cash flow minus SBC	$-7.6M
Net cash flow	$2M
Net income	$-9.1M
Operating cash flow minus SBC	$-7.6M
Operating income	$-9.1M
Stock-based compensation	$741,824

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$1.20
Debt / equity	0
Interest coverage	-1,480.55
Long-term assets	$287,181
Long-term liabilities	$0
Net cash (debt)	$7.6M
Net cash / market cap	107.75%
Net cash growth	35.06%
Net debt / equity	-1.31
Piotroski F-Score	1
Property, plant and equipment	$287,181
Shareholders' equity	$5.8M
Tangible book value	$5.8M
Tangible book value per share	$1.20
Total assets	$8.5M
Total cash	$7.6M
Total debt	$0
Total liabilities	$2.7M
WACC	5.74%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$8.3M
Current liabilities	$2.7M
Current ratio	3.01
Net working capital	$-2.1M
Quick ratio	2.77
Working capital	$5.5M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-311.13%
Dividend yield	0%
Shareholder yield	-311.13%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$1.31
1D price change	16.8%
1M price change	6.57%
1M total return	6.57%
1W price change	29.2%
1W total return	29.2%
1Y price change	-42.29%
1Y return CAGR	-42.31%
1Y total return	-42.29%
20-day SMA	$1.27
200-day SMA	$1.47
3M price change	11.45%
3M total return	11.45%
3Y price change	-99.02%
3Y return CAGR	-78.57%
3Y total return	-99.02%
50-day SMA	$1.53
50-day SMA vs 200-day SMA	50over200
52-week high	$2.61
52-week high date	2025-11-05
52-week low	$0.84
52-week low date	2026-04-13
5Y price change	-99.95%
5Y return CAGR	-78.25%
5Y total return	-99.95%
6M price change	30.36%
6M total return	30.36%
After-hours change	4.11%
After-hours close	$1.46
After-hours price	$1.52
All-time high	$45,292.48
All-time high date	2021-06-15
All-time low	$0.84
All-time low date	2026-04-13
Average true range (ATR)	$0.13
Average volume	28.8K
Beta (1Y)	2.94
Beta (2Y)	0.87
Beta (5Y)	0.27
Change from 52-week high	-44.06%
Change from 52-week low	73.81%
Change from all-time high	-100%
Change from all-time low	73.81%
Change from open	17.74%
Day's gap	-0.8%
Dollar volume	$352,222
High price	$1.53
Low price	$1.24
Monthly RSI	10.25
Open price	$1.24
Position in 52-week range	76.92%
Premarket change	3.76%
Premarket close	$1.46
Premarket price	$1.51
Premarket volume	5K
Previous close	$1.25
Price vs 150-day SMA	11.71%
Price vs 20-day SMA	15.05%
Price vs 200-day SMA	-0.41%
Price vs 50-day SMA	-4.39%
Relative volume	8.39
Return from IPO open	-100%
Return from IPO price	-70.8%
RSI	58.41
Sharpe ratio	-0.3
Sharpe ratio (3Y)	-0.68
Sharpe ratio (5Y)	-0.77
Sortino ratio	-0.34
Sortino ratio (3Y)	-1.32
Sortino ratio (5Y)	-1.37
Volume	241.2K
Weekly RSI	48.34
YTD price change	-19.78%
YTD total return	-19.78%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	4.8M
Float percentage	99.75%
Shares change (QoQ)	12.47%
Shares change (YoY)	311.13%
Shares held by insiders	0.02%
Shares held by institutions	26.89%
Shares outstanding	4.8M
Short % of float	0.71%
Short % of shares	0.71%
Short ratio	0.4 days

Deeper analysis on ALZN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ALZN report

Is a complete ALZN research report available?

No complete published report is available for Alzamend Neuro, Inc. (ALZN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Alzamend Neuro, Inc. (ALZN)

Price

Financial snapshot

Fair-value bridge

Latest news · ALZN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ALZN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ALZN

Frequently asked questions